These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36897735)

  • 21. Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
    Zhu P; Wang Y; Zhang W; Liu X
    Medicine (Baltimore); 2021 Jan; 100(4):e24339. PubMed ID: 33530227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review.
    Kanabar SS; Tiwari A; Soran V; Balendran P; Price M; Turner AM
    Thorax; 2022 Dec; 77(12):1163-1174. PubMed ID: 35688624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of PD‑1/PD‑L1 inhibitors combined with chemotherapy in patients with advanced gastric or gastro‑esophageal junction cancer: A systematic review and meta‑analysis.
    Su S
    Oncol Lett; 2023 Sep; 26(3):373. PubMed ID: 37564826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. External beam radiotherapy for unresectable hepatocellular carcinoma.
    Abdel-Rahman O; Elsayed Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011314. PubMed ID: 28267205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
    Huang D; Ke L; Cui H; Li S
    BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang Y; Deng L; Yang Y; Zhang T; Wu Y; Wang L; Bi N
    Clin Lung Cancer; 2022 Mar; 23(2):95-107. PubMed ID: 34284948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
    Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
    Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
    Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
    Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
    Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
    Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis.
    Inoue T; Narukawa M
    Cancer Control; 2022; 29():10732748221140694. PubMed ID: 36748438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials.
    Elmakaty I; Abdo R; Elsabagh A; Elsayed A; Malki MI
    Cancer Cell Int; 2023 May; 23(1):90. PubMed ID: 37170090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
    Nie RC; Zhao CB; Xia XW; Luo YS; Wu T; Zhou ZW; Yuan SQ; Wang Y; Li YF
    Biomed Res Int; 2020; 2020():5059079. PubMed ID: 32461994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis.
    Papathanassiou M; Tamposis I; Exarchou-Kouveli KK; Kontou PI; de Paz AT; Mitrakas L; Samara M; Bagos PG; Tzortzis V; Vlachostergios PJ
    Front Oncol; 2022; 12():996553. PubMed ID: 36531034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Brito ABC; Camandaroba MPG; de Lima VCC
    Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials.
    Banna GL; Signori A; Curioni-Fontecedro A; Cortellini A; Ponzano M; Giunta EF; Rebuzzi SE; Chan S; Gebbia V; van Eeden R; Addeo A; Ottensmeier C
    Eur J Cancer; 2022 May; 166():287-299. PubMed ID: 35358809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
    Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.